Individualized monitoring post-amyloid clearing therapy
Enrolling By Invitation
99 years and younger
All
Phase
N/A
50 participants needed
1 Location
Brief description of study
Primary Objective:
To determine changes in neurodegeneration over the first year of treatment with anti-amyloid monoclonal antibodies Secondary Objectives:
To identify measures that detect and monitor neuroinflammation during anti-amyloid treatment. To explore the interaction between neuroinflammation and neurodegeneration Primary Endpoint: Neuroimaging and blood-based measures of neurodegeneration, cognitive performance Secondary Endpoints: Neuroimaging and blood-based measures of neuroinflammation, cognitive performance
To determine changes in neurodegeneration over the first year of treatment with anti-amyloid monoclonal antibodies Secondary Objectives:
To identify measures that detect and monitor neuroinflammation during anti-amyloid treatment. To explore the interaction between neuroinflammation and neurodegeneration Primary Endpoint: Neuroimaging and blood-based measures of neurodegeneration, cognitive performance Secondary Endpoints: Neuroimaging and blood-based measures of neuroinflammation, cognitive performance
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
21 Aug 2024.
Study ID: 855610
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
